Design: PD-L1 expression was correlated with several pathologic and clinical parameters in tumor and tumor immune cells (ICs; CD3, CD4, CD8, CD20, and CD68) using the Ventana antibody (SP263) in 43 BCs, 48 paired mets in LNs, and 47 distant mets. Results: There was 100% agreement for PD-L1 expression on tumor and ICs between BC and immune cells and matched LNs. Overexpression correlated with higher grade, ER-, PR-, TN-, and highly proliferative tumors (P < .001). In LNs, the high positivity rate was driven by TN (70% vs 5%; P < .0001). In contrast, there was significantly near total absence of PDL-1 expression in distant mets compared to BC and LNs (2%-4% in mets vs 17-20% in BC and LN, P = .009). ICs density varied in BC and metastatic tumors with predominance of CD3 and CD68, and near total absence of CD20 cells. PD-L1 expression was mainly associated with CD68 cells. There were consistently higher numbers of CD3 (CD8 > CD4) than CD20 cells in primary and metastatic tumors. Conclusion: PDL1 is differentially expressed in primary BC and regional nodal disease. Its expression is significantly associated with aggressive tumor behavior. In contrast, that differential expression was lost in distant mets. Correlation of PDL1 expression in PBC and its microenvironment may be useful for further classification of BC and development of new treatment strategies.
Objectives:
Obtaining clinical samples that contain RNA of sufficient quality and quantity for next-generation sequencing is costly and challenging in resource-poor areas, in part due to the complexity of transporting whole blood samples which require dry ice. In this study, our aim was to optimize messenger RNA extraction from dried blood spots (DBS) and to determine whether this RNA was comparable to whole blood RNA preserved in Tempus tubes (Applied Biosystems, Foster City, CA). Methods: We collected single phlebotomy samples from eight adults in rural Tanzania. Blood was placed immediately into Tempus tubes and spotted onto Whatman Protein Saver 903 cards (GE Healthcare Life Sciences, Buckinghamshire, UK). We varied methods of RNA extraction from DBS and assessed the resulting quality and concentration of RNA. We then compared transcriptomes generated from our optimized DBS extraction technique with those from Tempus tubes. We used R to analyze the mapped transcripts and DESeq2 to normalize the count data. Then we compared log 2 normalized gene expression between paired DBS and whole blood using Spearman correlation coefficients and MA plots. Results: The optimal DBS RNA extraction used eight 3 mm DBS punches, bead beater disruption at maximum speed for 60 seconds, extraction by Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare Life Sciences), and purification with Zymo RNA Concentrator kit (Zymo Research, Irvine, CA). Spearman correlations of optimal DBS extraction vs whole blood transcriptomes showed that the results were similar with each method, ranging from 0.887 to 0.941.
Conclusion:
We demonstrated that RNA of sufficient quality and quantity for transcriptome generation can be extracted from DBS, and correlates highly with transcriptomes generated from Tempus tubes. To our knowledge, this is the first study to demonstrate the feasibility of using DBS for transcriptome analysis, which has less burdensome requirements for sample procurement and transportation. Interpace Diagnostics, Pittsburgh, PA Introduction: Thyroid nodules frequently undergo fine needle aspiration (FNA) to discriminate between benign vs malignant disease. Parathyroid processes in the form of hyperplasia (PH), adenoma (PA), and carcinoma (PC) can mimic thyroid nodular disease cytologically leading to indeterminate diagnosis. Molecular analysis, based on mutational analysis and/or RNA expression profiling, and designed for thyroid neoplasia, is often used as an ancillary tool. We sought discriminating features in thyroid molecular testing that would identify parathyroid tissue and indicate specific parathyroid disease states. Methods: Eight FFPE tissue specimens representing pairs of normal, hyperplastic, adenomatous, and carcinomatous parathyroid lesions underwent combined mutational and microRNA expression profiling designed to differentiate thyroid neoplasia. Mutational analysis targeted common thyroid mutations (BRAF, HRAS, KRAS, NRAS, PIK3CA, PAX8/PPAR, and RET/PTC translocation) on a next-generation sequencing platform (Illumina). MicroRNA (miR) expression profiling targeted 10 specific miRs showing over and under expression in thyroid follicular cell neoplasia. Messenger RNA expression of PAX8 and NKX2.1, unique to thyroid follicular cells, was used as markers for thyroid origin of nucleic acid. Results: Microdissected FFPE yielded adequate nucleic acid for this thyroid molecular testing approach. All parathyroid specimens lacked messenger RNA expression of PAX8 and NKX2.1, indicating absence of thyroid follicle lining cells. None of these parathyroid specimens manifest common somatic mutations seen in thyroid neoplasia. miR expression profiling, using criteria applied to thyroid follicular neoplasia, would have indicated thyroid malignancy if inappropriately assumed to be thyroid. Specific relative miR expression levels differentiated each of the parathyroid states. Normal parathyroid underexpressed miR138. PH underexpressed miR31, 204, and 551. PA overexpressed miR29b, 146, and 375. PC showed hyperexpression of miR31, 204, and 551. Conclusion: Parathyroid lesion can confound FNA cytology diagnosis of nodules presumed to be of thyroid origin. In this initial study ancillary molecular testing can affirm parathyroid tissue origin (messenger RNA expression) and miR expression profiling appears capable of differentiating between parathyroid disease states supporting further confirmatory studies. The approach is effective on fixative-treated specimens. Introduction: Hepatitis C virus (HCV) infection, estimated in 3% of the world's population, remains a major risk factor for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Based on the recognition of single-stranded viral RNA, TLR7 and TLR8 have been suggested to play important roles in antiviral immune responses to HCV. The miRNAs, endogenously expressed small noncoding RNAs, are known to promote mRNA degradation and block protein translation. In the present study, the specific candidate miRNAs that influence HCV protein-modulated TLR7/8 expression and subsequent signal modulation were investigated. Methods: miRNA microarray analysis was performed to screen for the miRNAs expression in HCV structure proteins (core, E1, and E2) stably transfected HepG 2 cells, and miRBase was used to predict the interaction between these miRNAs and TLR7/8 gene. miR-494-3p and miR942-3p were identified and validated. A total of 100 serum samples (30 samples from controls, 70 samples from HCV-infected patients) were collected. The levels of the two, miR-494-3p and miR942-3p, were then detected by probe-based stem-loop quantitative reverse-transcriptase PCR. Results: We found that the expression of serum miR-494-3p and miR942-3p was distinctly increased in HCV patients compared with controls (mean ± SEM: 917.7 ± 192.2 vs 32.5 ± 14.2, P < .001 and 1615.0 ± 516.3 vs 8.0 ± 5.4, P < .001). In addition, interferon treatment significantly decreased miR942-3p expression in HCV patients (mean ± SEM: 67200 ± 55000 vs 263400 ± 195900, P = .03).
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Structure Proteins of Hepatitis C Induce miR-494-3p and miR942-3p Expression
Conclusion:
The expression of miR-494-3p and miR942-3p in serum were significantly up-regulated in patients with HCV infection. However, the modulation mechanisms of miR494-3p and miR942-3p on TLR7/8 need further investigation.
Epigenomic Remodeling of the PAX8 Cistrome in Ovarian Cancer
Anna Budina-Kolomets, Ronny Drapkin, MD, PhD, Kevin Elias, MD; University of Pennsylvania, Philadelphia Several lineage-survival factors that operate during normal lineage development but become deregulated in the process of carcinogenesis were exploited as key oncogenic dependencies during tumor progression. However, this newly recognized mechanism of lineage addiction has not been studied in the context of high-grade serous ovarian cancers (HGSOCs). PAX8 is a lineage-defining transcription factor for Müllerian epithelia, which is expressed in both normal fallopian tube secretory epithelial cells (FTSECs) and their malignant counterpart, HGSOCs. Pax8 -/-female mice display infertility due to a functional defect in the development of the female reproductive tract. In addition, PAX8 is the single most differentially expressed gene when comparing ovarian cancer cell lines to all other cancer cell lines in the Cancer Cell Line Encyclopedia. Loss of PAX8 in ovarian cancer cell lines leads to apoptosis and decreased tumorigenicity, while cancer cell lines from other organ sites are unaffected. Here we hypothesize that PAX8 acquires different functions after malignant transformation and targeting the fallopian tube developmental program governed by PAX8 may serve as the basis for new ovarian cancer therapies. Using whole transcriptome shotgun sequencing (RNA-Seq) after PAX8 knockdown and ChIP-Seq, we show that FTSECs and HGSOCs are distinguished by marked reprogramming of the PAX8 cistrome. Genes that are significantly altered between FTSECs and HGSOCs are enriched near PAX8 binding sites. These sites are also near TEAD binding sites, and these transcriptional changes may be related to PAX8 interactions with the TEAD/YAP1 signaling pathway. These data suggest that transcriptional changes after transformation in ovarian cancer are closely related to epigenetic remodeling in lineage-specific transcription factors. Given the ubiquity of PAX8 expression on ovarian tumors, detailed examination of PAX8-associated cellular dependencies may reveal new aspects of the ovarian cancer pathogenesis and uncover selective vulnerabilities of tumor cells that will guide therapeutic approaches.
